About Ribonuclease P protein subunit p40
Ribonuclease P protein subunit p40 (RPP40) is a protein
from Homo sapiens identified by UniProt accession
O75818, 363 residues long.
MolForge cross-references it against 0 known binders and
14 disease associations.
Target properties
| Protein name | Ribonuclease P protein subunit p40 |
|---|
| UniProt accession | O75818 |
|---|
| Gene | RPP40 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 363 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (14)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.48
- keratinocyte carcinoma · score 0.22
- squamous cell carcinoma · score 0.22
- basal cell carcinoma · score 0.22
- neoplasm · score 0.07
- cancer · score 0.03
- uterine corpus endometrial carcinoma · score 0.01
- triple-negative breast cancer · score 0.00
- systemic scleroderma · score 0.00
- acute myeloid leukemia · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75818-F1 | alphafold | PREDICTED | 91.63 | — |
Amino-acid sequence (363 residues)
MATLRRLREA PRHLLVCEKS NFGNHKSRHR HLVQTHYYNY RVSFLIPECG ILSEELKNLV MNTGPYYFVK NLPLHELITP EFISTFIKKG SCYALTYNTH IDEDNTVALL PNGKLILSLD KDTYEETGLQ GHPSQFSGRK IMKFIVSIDL MELSLNLDSK KYERISWSFK EKKPLKFDFL LAWHKTGSEE STMMSYFSKY QIQEHQPKVA LSTLRDLQCP VLQSSELEGT PEVSCRALEL FDWLGAVFSN VDLNNEPNNF ISTYCCPEPS TVVAKAYLCT ITGFILPEKI CLLLEHLCHY FDEPKLAPWV TLSVQGFADS PVSWEKNEHG FRKGGEHLYN FVIFNNQDYW LQMAVGANDH CPP
Explore Ribonuclease P protein subunit p40 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets